Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 1000
Summary
- Conditions
- Africa
- Alcohol Use Disorder
- Antiretroviral Therapy
- Hepatitis B Virus
- HIV
- Liver Fibrosis
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Both males and females
Description
The study will take place during routinely scheduled ART visits as per Ministry of Health guidelines. Routinely collected programmatic data will be used to assess general HIV outcomes (CD4 response, loss to follow-up, death) as well as collecting study specific data (hepatitis testing, questionnaire...
The study will take place during routinely scheduled ART visits as per Ministry of Health guidelines. Routinely collected programmatic data will be used to assess general HIV outcomes (CD4 response, loss to follow-up, death) as well as collecting study specific data (hepatitis testing, questionnaire regarding risk factors for hepatitis/liver disease, and non-invasive liver scan) to address other aims. The study will be implemented at two sites in Southern Africa (Zambia and Mozambique) with a total enrollment across all sites of 1,900 participants. The Zambia site will only enroll 900.
Tracking Information
- NCT #
- NCT02060162
- Collaborators
- Centre for Infectious Disease Research in Zambia
- University of Bern
- Investigators
- Principal Investigator: Roma Chilengi, MD Centre for Infectious Disease Research in Zambia Principal Investigator: Michael Vinikoor, MD Centre for Infectious Disease Research in Zambia
Get Well Soon